<DOC>
	<DOCNO>NCT02332499</DOCNO>
	<brief_summary>The purpose study compare effect safety Anlotinib placebo patient metastatic colorectal cancer refractory standard chemotherapy .</brief_summary>
	<brief_title>Study Anlotinib Patients With Metastatic Colorectal Cancer（mCRC） ( ALTER0703 )</brief_title>
	<detailed_description>Anlotibib ( AL3818 ) kind innovative medicine approve State Food Drug Administration（SFDA:2011L00661） research Jiangsu Chia-tai Tianqing Pharmaceutical Co. , Ltd.To compare effect safety Anlotinib placebo patient metastatic colorectal cancer refractory standard chemotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed date informed consent； 2 . Histological cytological documentation adenocarcinoma colon rectum； 3 . Subjects metastatic colorectal cancer ( Stage IV ) , With measurable disease ( use RECIST1.1 ) ； 4 . Progression within 3 month follow last administration approve standard therapy must include Fluorouracil derivative , Oxaliplatin , Irinotecan； 5 . ECOG PS:01 , Life expectancy 3 months； 6. main organ function normal； 7. main organ function normal； 1 . Prior treatment Anlotinib； 2 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study drug； 3 . Known brain metastases； 4. patient severe fail controlled diseases； 5. patient occur venous thromboembolic event within 6 months；</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Anlotinib</keyword>
	<keyword>Metastatic Colorectal Cancer （mCRC）</keyword>
	<keyword>ALTER0703</keyword>
</DOC>